Every 10-Q that Vera Therapeutics, Inc. (VERA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow VERA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VERA filings page.
Vera Therapeutics, Inc. reported a larger net loss as it ramps up commercialization of its first FDA‑approved product, TRUTAKNA, for IgA nephropathy. For the six months ended June 30, 2026, the company recorded a net loss of $230.5 million, compared with $128.2 million a year earlier, driven by higher research and development and sharply higher general and administrative spending.
Total operating expenses rose to $237.6 million from $137.3 million, including $146.1 million in research and development and $91.5 million in general and administrative costs, reflecting increased headcount, stock‑based compensation, clinical trials, drug manufacturing, and commercial launch preparation. Cash, cash equivalents and marketable securities were $499.2 million as of June 30, 2026, down from $714.6 million at year‑end, after $206.8 million of operating cash outflows in the first half. Long‑term debt outstanding under the 2025 loan agreement was $75.0 million.
On July 7, 2026, after the quarter end, the FDA granted accelerated approval to TRUTAKNA based on Phase 3 data showing a 46% proteinuria reduction from baseline and a 42% reduction versus placebo at 36 weeks, and Vera expects only limited product revenue to begin in the third quarter of 2026.
Vera Therapeutics reported a larger Q1 2026 loss as it ramped up spending to advance its lead kidney drug atacicept toward potential approval. Net loss widened to $121.0 million from $51.7 million a year earlier, driven by sharply higher research, manufacturing and commercialization costs.
Research and development expenses more than doubled to $86.0 million, including a $15.0 million milestone payment after the FDA accepted the Biologics License Application for atacicept in IgA nephropathy. General and administrative costs rose to $39.1 million as Vera built commercial and medical affairs capabilities. The company ended the quarter with $596.8 million in cash, cash equivalents and marketable securities and expects this to fund operations for at least 12 months. Atacicept’s Phase 3 trial met its proteinuria endpoint, and the FDA granted priority review with a PDUFA target action date of July 7, 2026.
Vera Therapeutics (VERA) filed its Q3 2025 10‑Q, showing a larger quarterly net loss as it advances late-stage programs and scales operations. Net loss was $80.3 million (vs. $46.6 million a year ago), driven by higher operating expenses of $83.9 million with research and development at $56.5 million and general and administrative at $27.5 million. Basic and diluted net loss per share was $1.26.
Cash, cash equivalents and marketable securities were $497.4 million as of September 30, 2025, compared with $640.9 million at year-end 2024. Year-to-date net cash used in operating activities was $171.1 million. The company reiterated it believes its liquidity will fund operations for at least the next 12 months.
Vera refinanced its debt and entered a new loan facility of up to $500.0 million on June 2, 2025, with $75.0 million funded at closing and additional tranches available upon milestones and lender discretion. Long-term debt carried value was $74.6 million. The company highlighted positive primary endpoint results from the pivotal ORIGIN 3 Phase 3 trial of atacicept in IgAN and noted FDA Breakthrough Therapy Designation based on earlier Phase 2b data.